Drug treatment of hyperkinetic movement disorders.
Fahn
S
S
Department of Neurology, Columbia University College of Physicians & Surgeons, New York, New York.
D001569:Benzodiazepines / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism / Q000502:physiology; D004409:Dyskinesia, Drug-Induced; D006801:Humans; D006948:Hyperkinesis / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D007980:Levodopa / Q000627:therapeutic use*; D009069:Movement Disorders / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D010277:Parasympathomimetics / Q000627:therapeutic use*
D010277:Parasympathomimetics; D001569:Benzodiazepines; D007980:Levodopa; D001905:Botulinum Toxins; D004298:Dopamine